From 1 March 2026, important updates to the Medicare Benefits Schedule (MBS) have expanded access to Medicare-rebated speech pathology services for children and young people.
We’re genuinely pleased to see this change. For many families, funding can delay early support — and early intervention is critical when it comes to communication development.
Here’s what you need to know.
The M10 allied health item group provides Medicare rebates for eligible children and young people with specific neurodevelopmental or medical conditions that significantly impact functioning.
As of 1 March 2026, eligibility now includes additional speech-related diagnoses — improving access for children who previously did not qualify.
A child or young person may be eligible if they:
Are under 25 years of age
Have a referral from a GP, consultant physician or specialist
Have a diagnosis (or suspected diagnosis) of an eligible condition
Neurodevelopmental & genetic conditions
Autism Spectrum Disorder (ASD)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Cerebral palsy
Down syndrome
Fragile X syndrome
Moderate to severe intellectual disability
Speech & communication conditions (expanded March 2026)
Stuttering
Speech sound disorder, including:
Articulation disorder
Phonological disorder
Childhood apraxia of speech
Dysarthria
Cleft lip and/or palate
If you’re unsure whether your child fits within this criteria, our team can help you clarify next steps.
Under the M10 item group, eligible clients can access:
Up to 8 allied health assessment sessions (lifetime limit)
Up to 20 allied health treatment sessions (lifetime limit)
Medicare provides a rebate per session. Depending on session fees, there may be a gap payment.
Speech sound disorders and stuttering are not “just phases.”
They can impact:
Literacy development
Classroom participation
Confidence
Social connection
This expansion recognises the importance of early, evidence-based speech pathology support.
If funding has previously been a barrier, now is the time to revisit your options. For alternative Medicare options, and other available funding, see our funding page.
